Lack of Pharmacokinetic Interaction between the Oral Anti-Influenza Prodrug Oseltamivir and Aspirin
- 1 June 2002
- journal article
- clinical trial
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 46 (6) , 1993-1995
- https://doi.org/10.1128/aac.46.6.1993-1995.2002
Abstract
Twelve volunteers completed a two-sequence, three-way crossover study of a single 900-mg aspirin dose and multiple doses of 75 mg of oseltamivir in the absence and presence of 900 mg of aspirin. The plasma and urine results demonstrated no pharmacokinetic interaction between oseltamivir and aspirin.Keywords
This publication has 8 references indexed in Scilit:
- The Anti-Influenza Drug Oseltamivir Exhibits Low Potential to Induce Pharmacokinetic Drug Interactions via Renal Secretion—Correlation of in Vivo and in Vitro StudiesDrug Metabolism and Disposition, 2002
- Pharmacokinetics and Dosage Recommendations for an Oseltamivir Oral Suspension for the Treatment of Influenza in ChildrenPediatric Drugs, 2001
- Optimisation of alachlor solid-phase microextraction from water samples using experimental designJournal of Chromatography A, 2000
- Development of a high-performance liquid chromatographic–mass spectrometric assay for the specific and sensitive quantification of Ro 64-0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urineJournal of Chromatography B: Biomedical Sciences and Applications, 2000
- Clinical Pharmacokinetics of the Prodrug Oseltamivir and its Active Metabolite Ro 64-0802Clinical Pharmacokinetics, 1999
- Pharmacokinetics of acetylsalicylic acid and its metabolites at low doses: a compartmental modeling.1995
- Drug Interactions Involving Aspirin (Acetylsalicylic Acid) and Salicylic AcidClinical Pharmacokinetics, 1989
- Clinical Pharmacokinetics of the SalicylatesClinical Pharmacokinetics, 1985